Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States
We analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment. The National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment...
Gespeichert in:
| Veröffentlicht in: | HPB (Oxford, England) England), 2022-10, Vol.24 (10), p.1688-1696 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1696 |
|---|---|
| container_issue | 10 |
| container_start_page | 1688 |
| container_title | HPB (Oxford, England) |
| container_volume | 24 |
| creator | Kaltenmeier, Christof Stacchiotti, Silvia Gronchi, Alessandro Sapisochin, Gonzalo Liu, Hao Ashwat, Eishan Gunabushanam, Vikraman Reddy, Dheera Thompson, Ann Geller, David Tohme, Samer Zureikat, Amer Molinari, Michele |
| description | We analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment.
The National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment groups: no surgical therapy, ablation, liver resection or liver transplantation. Demographics and clinical characteristics were compared, and Kaplan Meier functions and Cox-regression were used for unadjusted and adjusted survival analyses.
Among a total of 334 patients, 218 (65.2%) were managed non-surgically, 74 (22.1%) underwent hepatic resections, 35 (10.4%) underwent liver transplantation and 7 (2.1%) underwent ablations. The overall median survival was 111 months (95%CI 73–149) after liver transplantation, 69 months (95%CI 45–92) after hepatic resection, 38 months (95%CI 0–78) after ablation and 80 months (95%CI 70–90) for patients managed by watchful waiting (P |
| doi_str_mv | 10.1016/j.hpb.2022.03.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9827415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1365182X22000909</els_id><sourcerecordid>2659605322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-a47c36b07ba681ba9b713d99fdedbb7be5c1b886a24d610168d8c4e200ca80ba3</originalsourceid><addsrcrecordid>eNp9UcuKFDEUDaI4Lz_AjWTppso8KlUpBEEGdYQBF87A7GIet7vTVJI2SQ_496bpcXA2s7qXe88593EQektJTwkdP2z7zc70jDDWE94Tyl-gUzpMU8fENLxsOR9FRyW7O0FnpWwJYY02v0YnXAgySM5O0a-bDLoGiBWH5PTiq4eCdXR4SXHdVcgBp321KbRyWuEN7HT1tsWg49oniC7VDSw-BY19xC3Ht9FXcPhn1RXKBXq10kuBNw_xHN1-_XJzedVd__j2_fLzdWcHQWunh8ny0ZDJ6FFSo2czUe7meeXAGTMZEJYaKUfNBjcejpdO2gEYIVZLYjQ_R5-Ouru9CeBsuyjrRe2yDzr_UUl79bQT_Uat072aJZsGKprA-weBnH7voVQVfLGwLDpC2hfFRjGPRHDGGpQeoTanUjKsHsdQog7Lqa1qzqiDM4pw1ZxpnHf_7_fI-GdFA3w8AqB96d5DVsV6iBacz2Crcsk_I_8XUHOh1A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2659605322</pqid></control><display><type>article</type><title>Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kaltenmeier, Christof ; Stacchiotti, Silvia ; Gronchi, Alessandro ; Sapisochin, Gonzalo ; Liu, Hao ; Ashwat, Eishan ; Gunabushanam, Vikraman ; Reddy, Dheera ; Thompson, Ann ; Geller, David ; Tohme, Samer ; Zureikat, Amer ; Molinari, Michele</creator><creatorcontrib>Kaltenmeier, Christof ; Stacchiotti, Silvia ; Gronchi, Alessandro ; Sapisochin, Gonzalo ; Liu, Hao ; Ashwat, Eishan ; Gunabushanam, Vikraman ; Reddy, Dheera ; Thompson, Ann ; Geller, David ; Tohme, Samer ; Zureikat, Amer ; Molinari, Michele</creatorcontrib><description>We analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment.
The National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment groups: no surgical therapy, ablation, liver resection or liver transplantation. Demographics and clinical characteristics were compared, and Kaplan Meier functions and Cox-regression were used for unadjusted and adjusted survival analyses.
Among a total of 334 patients, 218 (65.2%) were managed non-surgically, 74 (22.1%) underwent hepatic resections, 35 (10.4%) underwent liver transplantation and 7 (2.1%) underwent ablations. The overall median survival was 111 months (95%CI 73–149) after liver transplantation, 69 months (95%CI 45–92) after hepatic resection, 38 months (95%CI 0–78) after ablation and 80 months (95%CI 70–90) for patients managed by watchful waiting (P < 0.001). After adjustment, patients who underwent liver transplantation were found to have a better survival when compared to other therapies (Hazard Ratio: 0.61, 95% Confidence Interval: 0.38–0.97, p = 0.035).
This study reports the outcomes of the largest cohort of patients with HEHE. The longest survival was observed after liver transplantation, followed by non-surgical management and hepatic resection. Because of selection bias, future studies to better characterize what criteria should be used for the selection of treatment modalities for HEHE are urgently needed.</description><identifier>ISSN: 1365-182X</identifier><identifier>EISSN: 1477-2574</identifier><identifier>DOI: 10.1016/j.hpb.2022.03.013</identifier><identifier>PMID: 35504832</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Hemangioendothelioma - surgery ; Hemangioendothelioma, Epithelioid - surgery ; Humans ; Liver ; Liver Neoplasms - surgery ; Retrospective Studies ; Treatment Outcome ; United States</subject><ispartof>HPB (Oxford, England), 2022-10, Vol.24 (10), p.1688-1696</ispartof><rights>2022 International Hepato-Pancreato-Biliary Association Inc.</rights><rights>Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-a47c36b07ba681ba9b713d99fdedbb7be5c1b886a24d610168d8c4e200ca80ba3</citedby><cites>FETCH-LOGICAL-c451t-a47c36b07ba681ba9b713d99fdedbb7be5c1b886a24d610168d8c4e200ca80ba3</cites><orcidid>0000-0002-4703-3534 ; 0000-0003-0974-7904 ; 0000-0002-9314-5844 ; 0000-0002-9763-6253</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827415/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827415/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35504832$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaltenmeier, Christof</creatorcontrib><creatorcontrib>Stacchiotti, Silvia</creatorcontrib><creatorcontrib>Gronchi, Alessandro</creatorcontrib><creatorcontrib>Sapisochin, Gonzalo</creatorcontrib><creatorcontrib>Liu, Hao</creatorcontrib><creatorcontrib>Ashwat, Eishan</creatorcontrib><creatorcontrib>Gunabushanam, Vikraman</creatorcontrib><creatorcontrib>Reddy, Dheera</creatorcontrib><creatorcontrib>Thompson, Ann</creatorcontrib><creatorcontrib>Geller, David</creatorcontrib><creatorcontrib>Tohme, Samer</creatorcontrib><creatorcontrib>Zureikat, Amer</creatorcontrib><creatorcontrib>Molinari, Michele</creatorcontrib><title>Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States</title><title>HPB (Oxford, England)</title><addtitle>HPB (Oxford)</addtitle><description>We analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment.
The National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment groups: no surgical therapy, ablation, liver resection or liver transplantation. Demographics and clinical characteristics were compared, and Kaplan Meier functions and Cox-regression were used for unadjusted and adjusted survival analyses.
Among a total of 334 patients, 218 (65.2%) were managed non-surgically, 74 (22.1%) underwent hepatic resections, 35 (10.4%) underwent liver transplantation and 7 (2.1%) underwent ablations. The overall median survival was 111 months (95%CI 73–149) after liver transplantation, 69 months (95%CI 45–92) after hepatic resection, 38 months (95%CI 0–78) after ablation and 80 months (95%CI 70–90) for patients managed by watchful waiting (P < 0.001). After adjustment, patients who underwent liver transplantation were found to have a better survival when compared to other therapies (Hazard Ratio: 0.61, 95% Confidence Interval: 0.38–0.97, p = 0.035).
This study reports the outcomes of the largest cohort of patients with HEHE. The longest survival was observed after liver transplantation, followed by non-surgical management and hepatic resection. Because of selection bias, future studies to better characterize what criteria should be used for the selection of treatment modalities for HEHE are urgently needed.</description><subject>Hemangioendothelioma - surgery</subject><subject>Hemangioendothelioma, Epithelioid - surgery</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver Neoplasms - surgery</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>1365-182X</issn><issn>1477-2574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcuKFDEUDaI4Lz_AjWTppso8KlUpBEEGdYQBF87A7GIet7vTVJI2SQ_496bpcXA2s7qXe88593EQektJTwkdP2z7zc70jDDWE94Tyl-gUzpMU8fENLxsOR9FRyW7O0FnpWwJYY02v0YnXAgySM5O0a-bDLoGiBWH5PTiq4eCdXR4SXHdVcgBp321KbRyWuEN7HT1tsWg49oniC7VDSw-BY19xC3Ht9FXcPhn1RXKBXq10kuBNw_xHN1-_XJzedVd__j2_fLzdWcHQWunh8ny0ZDJ6FFSo2czUe7meeXAGTMZEJYaKUfNBjcejpdO2gEYIVZLYjQ_R5-Ouru9CeBsuyjrRe2yDzr_UUl79bQT_Uat072aJZsGKprA-weBnH7voVQVfLGwLDpC2hfFRjGPRHDGGpQeoTanUjKsHsdQog7Lqa1qzqiDM4pw1ZxpnHf_7_fI-GdFA3w8AqB96d5DVsV6iBacz2Crcsk_I_8XUHOh1A</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Kaltenmeier, Christof</creator><creator>Stacchiotti, Silvia</creator><creator>Gronchi, Alessandro</creator><creator>Sapisochin, Gonzalo</creator><creator>Liu, Hao</creator><creator>Ashwat, Eishan</creator><creator>Gunabushanam, Vikraman</creator><creator>Reddy, Dheera</creator><creator>Thompson, Ann</creator><creator>Geller, David</creator><creator>Tohme, Samer</creator><creator>Zureikat, Amer</creator><creator>Molinari, Michele</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4703-3534</orcidid><orcidid>https://orcid.org/0000-0003-0974-7904</orcidid><orcidid>https://orcid.org/0000-0002-9314-5844</orcidid><orcidid>https://orcid.org/0000-0002-9763-6253</orcidid></search><sort><creationdate>20221001</creationdate><title>Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States</title><author>Kaltenmeier, Christof ; Stacchiotti, Silvia ; Gronchi, Alessandro ; Sapisochin, Gonzalo ; Liu, Hao ; Ashwat, Eishan ; Gunabushanam, Vikraman ; Reddy, Dheera ; Thompson, Ann ; Geller, David ; Tohme, Samer ; Zureikat, Amer ; Molinari, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-a47c36b07ba681ba9b713d99fdedbb7be5c1b886a24d610168d8c4e200ca80ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Hemangioendothelioma - surgery</topic><topic>Hemangioendothelioma, Epithelioid - surgery</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver Neoplasms - surgery</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaltenmeier, Christof</creatorcontrib><creatorcontrib>Stacchiotti, Silvia</creatorcontrib><creatorcontrib>Gronchi, Alessandro</creatorcontrib><creatorcontrib>Sapisochin, Gonzalo</creatorcontrib><creatorcontrib>Liu, Hao</creatorcontrib><creatorcontrib>Ashwat, Eishan</creatorcontrib><creatorcontrib>Gunabushanam, Vikraman</creatorcontrib><creatorcontrib>Reddy, Dheera</creatorcontrib><creatorcontrib>Thompson, Ann</creatorcontrib><creatorcontrib>Geller, David</creatorcontrib><creatorcontrib>Tohme, Samer</creatorcontrib><creatorcontrib>Zureikat, Amer</creatorcontrib><creatorcontrib>Molinari, Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>HPB (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaltenmeier, Christof</au><au>Stacchiotti, Silvia</au><au>Gronchi, Alessandro</au><au>Sapisochin, Gonzalo</au><au>Liu, Hao</au><au>Ashwat, Eishan</au><au>Gunabushanam, Vikraman</au><au>Reddy, Dheera</au><au>Thompson, Ann</au><au>Geller, David</au><au>Tohme, Samer</au><au>Zureikat, Amer</au><au>Molinari, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States</atitle><jtitle>HPB (Oxford, England)</jtitle><addtitle>HPB (Oxford)</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>24</volume><issue>10</issue><spage>1688</spage><epage>1696</epage><pages>1688-1696</pages><issn>1365-182X</issn><eissn>1477-2574</eissn><abstract>We analyzed the outcomes of patients with hepatic epithelioid hemangioendothelioma (HEHE) in the United States after stratification by their most definitive treatment.
The National Cancer Data Base was used to identify patients with HEHE between 2004 and 2018. Patients were divided in four treatment groups: no surgical therapy, ablation, liver resection or liver transplantation. Demographics and clinical characteristics were compared, and Kaplan Meier functions and Cox-regression were used for unadjusted and adjusted survival analyses.
Among a total of 334 patients, 218 (65.2%) were managed non-surgically, 74 (22.1%) underwent hepatic resections, 35 (10.4%) underwent liver transplantation and 7 (2.1%) underwent ablations. The overall median survival was 111 months (95%CI 73–149) after liver transplantation, 69 months (95%CI 45–92) after hepatic resection, 38 months (95%CI 0–78) after ablation and 80 months (95%CI 70–90) for patients managed by watchful waiting (P < 0.001). After adjustment, patients who underwent liver transplantation were found to have a better survival when compared to other therapies (Hazard Ratio: 0.61, 95% Confidence Interval: 0.38–0.97, p = 0.035).
This study reports the outcomes of the largest cohort of patients with HEHE. The longest survival was observed after liver transplantation, followed by non-surgical management and hepatic resection. Because of selection bias, future studies to better characterize what criteria should be used for the selection of treatment modalities for HEHE are urgently needed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35504832</pmid><doi>10.1016/j.hpb.2022.03.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4703-3534</orcidid><orcidid>https://orcid.org/0000-0003-0974-7904</orcidid><orcidid>https://orcid.org/0000-0002-9314-5844</orcidid><orcidid>https://orcid.org/0000-0002-9763-6253</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-182X |
| ispartof | HPB (Oxford, England), 2022-10, Vol.24 (10), p.1688-1696 |
| issn | 1365-182X 1477-2574 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9827415 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Hemangioendothelioma - surgery Hemangioendothelioma, Epithelioid - surgery Humans Liver Liver Neoplasms - surgery Retrospective Studies Treatment Outcome United States |
| title | Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20modalities%20and%20long-term%20outcomes%20of%20hepatic%20hemangioendothelioma%20in%20the%20United%20States&rft.jtitle=HPB%20(Oxford,%20England)&rft.au=Kaltenmeier,%20Christof&rft.date=2022-10-01&rft.volume=24&rft.issue=10&rft.spage=1688&rft.epage=1696&rft.pages=1688-1696&rft.issn=1365-182X&rft.eissn=1477-2574&rft_id=info:doi/10.1016/j.hpb.2022.03.013&rft_dat=%3Cproquest_pubme%3E2659605322%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2659605322&rft_id=info:pmid/35504832&rft_els_id=S1365182X22000909&rfr_iscdi=true |